Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.